Consolidated Investment Group LLC Has $3.25 Million Holdings in Zoetis Inc. $ZTS

Consolidated Investment Group LLC trimmed its position in Zoetis Inc. (NYSE:ZTS) by 15.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,200 shares of the company’s stock after selling 4,035 shares during the quarter. Consolidated Investment Group LLC’s holdings in Zoetis were worth $3,248,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Halbert Hargrove Global Advisors LLC lifted its holdings in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares during the period. REAP Financial Group LLC raised its position in Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after purchasing an additional 131 shares in the last quarter. NewSquare Capital LLC lifted its stake in Zoetis by 69.1% during the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after purchasing an additional 85 shares during the period. ORG Partners LLC boosted its holdings in Zoetis by 56.8% during the second quarter. ORG Partners LLC now owns 232 shares of the company’s stock valued at $37,000 after purchasing an additional 84 shares in the last quarter. Finally, Financial Consulate Inc. bought a new stake in shares of Zoetis in the 3rd quarter valued at approximately $39,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Bank of America downgraded Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 target price for the company. in a research report on Monday, December 15th. UBS Group cut their price objective on Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a report on Wednesday, November 5th. BTIG Research reaffirmed a “buy” rating and issued a $160.00 target price on shares of Zoetis in a report on Wednesday, December 3rd. Barclays started coverage on shares of Zoetis in a research report on Monday, December 8th. They set an “equal weight” rating and a $136.00 target price for the company. Finally, HSBC set a $140.00 price target on shares of Zoetis in a research report on Wednesday, December 10th. Six investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $160.18.

Zoetis Stock Down 0.4%

Shares of NYSE ZTS opened at $124.79 on Friday. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $177.40. The firm’s 50-day simple moving average is $123.21 and its 200 day simple moving average is $139.49. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. The company has a market cap of $54.99 billion, a price-to-earnings ratio of 21.01, a price-to-earnings-growth ratio of 2.53 and a beta of 0.97.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. During the same period in the previous year, the firm posted $1.58 earnings per share. The company’s revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date is Tuesday, January 20th. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s dividend payout ratio is 33.67%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.